Diagnostics and Drug Delivery Devices

Sysmex Corporation

Sysmex Corporation Downgrades Full-Year Fiscal 2026 Financial Forecast

6869

Sysmex (6869.T) reported a fiscal year profit of 35.5 billion yen, down 33.9% from the previous year, with operating profit at 51.83 billion yen, a 40.8% decline. Earnings per share fell to 56.89 yen from 86.05 yen. For the fiscal year ending March 31, 2027, the company anticipates a profit of 36.0 billion yen and net sales of 535.0 billion yen. Shares are currently trading at 1,343 yen, up 0.075%.

rttnews

Sysmex

Sysmex FY Net Profit Declines

SSMXY

The Hematology Analyzers and Reagents Market is projected to grow from USD 7.57 billion in 2026 to USD 10.33 billion by 2031, at a CAGR of 6.4%. The Asia Pacific region is expected to witness the highest growth rate, driven by increasing demand for advanced diagnostic tools and rising prevalence of blood-related diseases. The blood cancer segment is anticipated to dominate the market, accounting for 34% of revenue share in 2025. Key players include Sysmex Corporation, Danaher Corporation, and Siemens Healthineers.

prnewswire

Siemens Healthineers AG

Danaher

10:15 ETHematology Analyzers and Reagents Market worth $10.33 billion by 2031 | MarketsandMarkets™

Sysmex Corporation (OTCMKTS:SSMXY) reached a new 52-week low of $8.15 during trading, down from a previous close of $8.69. Citigroup downgraded the stock from "strong-buy" to "hold." Currently, Sysmex has an average rating of "hold" from analysts, with one buy and two hold ratings. The company reported $0.15 EPS for the last quarter, exceeding estimates, and had revenue of $837.32 million. Sysmex specializes in in vitro diagnostic solutions and has a market cap of $5.13 billion.

Market Beat

Citigroup

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Sysmex (OTCMKTS:SSMXY) Reaches New 12-Month Low  - Here's What Happened

Sysmex (TSE:6869) shares have seen a significant decline of 44.9% over the past year, closing at ¥1,467. A Discounted Cash Flow analysis suggests the stock is fairly valued at ¥1,567.57, indicating a 6.4% discount. The current P/E ratio of 20.4x is in line with industry averages, but below the estimated fair P/E of 26.6x, suggesting it may be undervalued. Investors are reassessing Sysmex's value amidst changes in the healthcare sector, prompting a closer look at its financial metrics and future projections.

Simplywall

Is Sysmex (TSE:6869) Now Fairly Priced After A 45% One Year Share Price Slide?

Sysmex Corporation(6869.JP)

Sysmex FY Net Profit Declines

10:15 ETHematology Analyzers and Reagents Market worth $10.33 billion by 2031 | MarketsandMarkets™

Sysmex (OTCMKTS:SSMXY) Reaches New 12-Month Low - Here's What Happened

Is Sysmex (TSE:6869) Now Fairly Priced After A 45% One Year Share Price Slide?